ARTA
ATXS

A.R.T. Advisors’s Astria Therapeutics ATXS Stock Holding History

A.R.T. Advisors’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,057
Closed -$94K – 1483
2017
Q4 		$94K Buy
1,057
+261
+33% +$30.7K ﹤0.01% 1262
2017
Q3 		$101K Sell
796
-1,056
-57% -$88.1K 0.01% 1207
2017
Q2 		$157K Buy
1,852
+1,073
+138% +$89.3K 0.01% 1199
2017
Q1 		$74K Buy
+779
New +$107K ﹤0.01% 1304

Other funds holding ATXS

SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
CV
Clarus Ventures Cambridge, Massachusetts $425M AUM 26.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
OC
Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

A.R.T. Advisors's ATXS Position: Q1 2018 in Review

A.R.T. Advisors sold out of Astria Therapeutics (ATXS) in Q1 2018, closing a stake of 1,057 shares — an estimated $94K sold.

A.R.T. Advisors first reported a position in ATXS in Q1 2017 and held it in 4 quarters. The position peaked at $157K in Q2 2017. 24 funds tracked by Wall St. Rank hold ATXS as of Q1 2018.

  • A.R.T. Advisors reported no remaining Astria Therapeutics position as of Q1 2018 after selling out during the quarter.
  • A.R.T. Advisors sold 1,057 Astria Therapeutics shares in Q1 2018, an estimated $94K.
  • A.R.T. Advisors first reported a position in Astria Therapeutics in Q1 2017 and held it in 4 quarters.
  • A.R.T. Advisors's Astria Therapeutics position peaked at $157K in Q2 2017.
  • 24 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2018.

Based on A.R.T. Advisors's 13F filing for Q1 2018, filed 15 May 2018.